Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics reported Q4 losses of $(1.46) per share, missing the $(0.92) estimate, and sales of $3.62M, below the $4.07M estimate. This represents an increase in losses from the previous year but a decrease in sales.
March 28, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agile Therapeutics reported a significant miss in both earnings and sales for Q4, with losses widening from the analyst estimates.
The reported earnings significantly missed analyst expectations, indicating potential operational or market challenges. This miss, especially in both earnings and sales, could lead to negative investor sentiment in the short term, impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100